Table 1.
Details of patients tested
| Patient number | Age | Sex | Year of diagnosis | Medications | UPDRS Part III–DBS ON | UPDRS Part III–DBS OFF |
|---|---|---|---|---|---|---|
| 1 | 56 | M | 1996 | Stalevo, amantadine | 22 | 34 |
| 2 | 47 | M | 2005 | Sinemet Plus, entacapone | 13 | 76 |
| 3 | 65 | M | 2000 | Stalevo, ropinorole, pergoline, rasagiline | 6 | 33 |
| 4 | 68 | M | 2006 | Sinemet Plus, amantadine | 19 | 41 |
| 5 | 65 | M | 2002 | Rasagiline, Sinemet Plus, apomorphine | 10 | 43 |
| 6 | 70 | M | 2000 | Madopar, entacapone | 3 | 16 |
Unified Parkinson's Disease Rating Scale (UPDRS) scores are with DBS ON and OFF (patients were on their medication in both cases). Sinemet Plus contains a combination of levodopa and carbidopa; Stalevo contains levodopa, carbidopa, and entacapone; and Madopar contains levodopa and benserazide.